A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become
available, extending progression-free and overall survival for patients in meaningful ways …

Multiple myeloma remains an incurable disease with the usual disease course requiring
induction therapy, autologous stem cell transplantation for eligible patients, and long-term …

Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …

Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …

Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti‐CD38
monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM) therapy …

Over the past decade, therapeutic options in multiple myeloma (MM) have changed
dramatically. Given the unprecedented efficacy of novel agents, the role of hematopoietic …

The increase in the number of therapeutic alternatives for both newly diagnosed and
relapsed/refractory multiple myeloma (RRMM) patients has widened the clinical scenario …

Simple Summary Multiple Myeloma (MM) is the most common cancer of the bone marrow
and remains incurable despite advances in novel therapy. The disease course is typically …

We evaluated the outcomes of 168 patients undergoing delayed or second autologous stem
cell transplant (ASCT) for relapsed multiple myeloma (MM) from 2010 to 2019. Overall …

The role of maintenance therapy after high-dose chemotherapy and first autologous
transplantation in multiple myeloma (MM) is well established. We explored the effect of …